659
Participants
Start Date
October 30, 2012
Primary Completion Date
November 12, 2024
Study Completion Date
November 12, 2024
Nivolumab
Sorafenib
Ipilimumab
Cabozantinib
Local Institution - 0005, Hong Kong
Local Institution - 0027, Taipei
Local Institution - 0024, Taipei
Local Institution - 0023, Taoyuan District
Local Institution - 0062, Marseille
Local Institution - 0059, Marseille
Local Institution - 0048, Washington D.C.
Local Institution - 0040, Rozzano
Local Institution - 0055, Milan
Local Institution - 0020, Madrid
Local Institution - 0018, Madrid
Local Institution - 0047, Atlanta
Local Institution - 0029, Hanover
Local Institution - 0003, Pamplona
Local Institution - 0053, Pensacola
Local Institution - 0032, Bologna
Local Institution - 0030, Essen
Local Institution - 0063, Meldola (FC)
Local Institution - 0061, Angers
Local Institution - 0056, Florence
Local Institution - 0060, Reims
Local Institution - 0058, Vandœuvre-lès-Nancy
Local Institution - 0028, Frankfurt
Local Institution - 0031, Heidelberg
Local Institution - 0042, Paris
The University Of Texas MD Anderson Cancer Center, Houston
Local Institution - 0034, Napoli
Local Institution - 0008, Los Angeles
Local Institution - 0064, Créteil
Local Institution - 0001, Portland
Local Institution - 0017, Singapore
Local Institution - 0009, Singapore
Local Institution - 0007, Singapore
Local Institution - 0049, Yokohama
Local Institution - 0036, Kashiwa-shi
Local Institution - 0037, Ōsaka-sayama
Local Institution - 0050, Kyoto
Local Institution - 0038, Kurume-shi
Local Institution - 0051, Saga
Local Institution - 0025, Boston
Local Institution - 0002, Ann Arbor
Local Institution - 0054, Hackensack
Local Institution - 0067, Paterson
Local Institution - 0065, Halifax
Local Institution - 0039, Toronto
Local Institution - 0022, Montreal
Local Institution - 0006, Hong Kong
Local Institution - 0035, Padua
Local Institution - 0070, San Juan
Local Institution - 0066, Seoul
Local Institution - 0021, Seoul
Local Institution - 0026, Seoul
Local Institution - 0016, Seoul
Local Institution - 0019, Barcelona
Local Institution - 0011, London
Local Institution - 0014, Manchester
Local Institution - 0012, Glasgow
Local Institution - 0015, Metropolitan Borough of Wirral
Local Institution - 0013, Birmingham
Local Institution - 0010, London
Lead Sponsor
Collaborators (1)
Ono Pharmaceutical Co. Ltd
INDUSTRY
Bristol-Myers Squibb
INDUSTRY